Chemo and Immunotherapy Sequence for High-Risk Triple-Negative Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two different sequences of chemotherapy combined with the immunotherapy drug pembrolizumab (Keytruda) before surgery for high-risk triple-negative breast cancer. It aims to see which order works better to shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer that has not spread to other parts of the body.
- Your tumor has at least 10% immune cells (called tumor-infiltrating lymphocytes) in a biopsy sample.
- You are 18 years or older and have not had chemotherapy or radiation for this cancer before.
- You have not received immunotherapy (like Keytruda) before, and you do not have an active autoimmune disease requiring strong medication.
- Your heart, kidney, and liver function are adequate, and you are generally active (ECOG 0 or 1).
- You are willing to provide tumor samples before and after the first treatment cycle.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.